Frequency of Infliximab Infusion Reactions

Save

A Canadian registry shows that in community-based infusion clinics, infusion reactions to IFX are uncommon and mild to moderate in nature.

Cosmic Etiology to RA and Polymyalgia Rheumatica

Save

Researchers at Johns Hopkins, Mayo Clinic and the NIH have determined that solar cycles and geomagnetic effects may account for the incidence of RA and PMR.

Expanding Global Biosimilar Market

Save

Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.

The EULAR 2015 Report- Friday

Save

These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.

The EULAR 2015 Report - Wednesday

Save

EULAR 2015 started the afternoon of Wednesday June 10th.

Rheumatic Manifestations of Chikungunya Virus

Save

Chikungunya is a new viral cause of fever and arthritis, especially in endemic areas like the caribbean. The chikungunya epidemic has grown significantly in the Western hemisphere with a total of 1,247,000 cases and 183 fatalities since

High Flare Rates with Drug Withdrawal in JIA

Save

While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.

Knee Implant Forecast from 2012 - 2018

Save

The global knee implants market was USD 8.4 billion in 2011, and it's forecasted to reach USD 15 billion in 2018, with compound annual growth rate of 8.64% during 2011 to 2018. The U.S.

Comorbidities Increasing in Arthritis Patients

Save

A CDC report shows comorbid conditions exist in 73.1% of all arthritis patients. Based on NHIS survey data, the number of patients with 2 or more comorbid conditions has increased from 21.8% in 2001 to 25.5% in 2012.  Most affected were older adults (≥65 years), women, wh

Medicare D and Costly Biologics

Save

25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics.  Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.

Prevalence of doctor-diagnosed arthritis and activity limitations

Save

52.5 million US adults (22.7%) have arthritis with half of these claiming activity limitation because of arthritis and pain.  Many arthritis patients have comorbid conditions including heart disease (49%), diabetes (47%) and obesity (31%).

RA Sarilumab Trials Meet Primary Endpoints

Save

Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.

Safety Reports & Updates – May 2015

Save

A Microneedle Pill as an Alternative to Injectable Drug

Save

Carl Schoellhammerhas just won the Lemelson-MIT National Collegiate Student Prize for his invention - the microneedle pill.

The Danger Model as an Alternative Cause of Autoimmunity

Save

The danger model was proposed by Matzinger as an alternative (or complement) to the traditional self-non-self (SNS) model of autoimmunity.

Pisetsky on Digital Infarcts and Rheumatoid Vasculitis

Save

"As scholars of disease have noted, RA today appears to be a less severe disease than it was when I started my career in the 1970s. Then, patients routinely ‘went up in smoke’ and rapidly became crippled, wasting away in a state we called ‘burnt out’.

Early DMARD Therapy Averts Cardiovascular Risk in RA

Save

A Finnish early RA register studied 14,878 incident RA patients from 2000-2008 and identified 1157 deaths.  Patients receiving DMARDs and MTX had lower mortality rates. The standardized moratility ratio for the entire cohort was reduced (0.57, 95% CI 0.52 to 0.62).

The National Prevalence of HLA-B27 in the U.S.

Save

HLA-B27 is found 6.1% of the US population, but with is seen in >90% patients with ankylosing spondylitis. HLA-B27 increases risk of spondylitis, uveitis and heart block. [Image credit: "HLA-B*2705" by Pdeitiker - Own work. Licensed under Public Domain via Wikimedia Commons]

Economic Impact of Biosimilars

Save

According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.

Hepatotoxicity and TNF Inhibitors

Save

Hepatic enzyme elevations with TNF inhibitor use is not uncommon.